HSP90 inhibitors for the treatment of cancer
By targeting cancers with HSP90AB1 or ATM gene mutations using Hsp90 inhibitors and synthetic lethality, the method addresses the limitations of existing Hsp90 inhibitors, achieving enhanced cancer cell inhibition and overcoming resistance, providing a more effective treatment for specific cancer types.
Patent Information
- Application Number
- PCT/US2024/030064
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-28
AI Technical Summary
Current Hsp90 inhibitors face challenges such as drug resistance and poor pharmacokinetic profiles, limiting their effectiveness in cancer treatment, and there is a need for novel Hsp90-targeted therapies that can overcome these issues.
The development of methods involving Hsp90 inhibitors, specifically targeting cancers with loss of function mutations or deletions in the HSP90AB1 or ATM genes, utilizing synthetic lethality to enhance cancer cell inhibition, and using a range of Hsp90 inhibitors like luminespib, ganetespib, and onalespib to treat cancers such as lung, colorectal, and uterine cancers.
This approach provides unexpectedly superior cancer cell inhibition and overcomes resistance issues, offering a more effective treatment strategy for specific cancer types by targeting vulnerabilities unique to cancer cells with HSP90AB1 or ATM gene mutations.
Smart Images

Figure US2024030064_28112024_PF_FP_ABST
Abstract
Description
HSP90 INHIBITORS FOR THE TREATMENT OF CANCERCROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 467,874 filed on May 19, 2023, the entirety of which is incorporated herein by reference.BACKGROUND
[0002] Heat shock protein 90 (Hsp90) may be a vital chaperone protein for regulating signaling pathways and correcting misfolded proteins in cancer cells by interacting with oncogenic client proteins and co-chaperones. The inhibition of Hsp90 chaperone machinery may provide for a potential approach to inhibit tumor survival, proliferation, invasion and migration. As cancer-targeted therapies, Hsp90 inhibitors may act by interrupting the ATPase activity of Hsp90, thus suppressing the oncogenic pathways in cancer cells. Hsp90 inhibitors have been classified into three categories: i) N-terminal domain (NTD) inhibitors; ii) C-terminal domain (CTD) inhibitors; and iii) isoform-selective inhibitors. While Hsp90 inhibitors may appear promising for the treatment of cancers, no Hsp90 inhibitor has been used in FDA approved clinical treatments due issues such as drug resistance, dose-limiting toxicity, and poor pharmacokinetic profiles. For example, in relation to drug resistance, some researchers have contemplated that Hsp90 inhibitors may enhance drug efflux activity of drug resistant cells.
[0003] Accordingly, there is a need for the development of novel Hsp90-targeted treatments for cancer-targeted therapies.BRIEF SUMMARY OF THE INVENTION
[0004] The present disclosure is based, in part, on the unique discovery that cancers may be associated with a loss of function genetic mutation or deletion of HSP90AB1 or an ataxia telangiectasia mutated (“ATM”) gene, and once identified, such cancers may be treated by administering (e.g., a therapeutically effective amount) a Hsp90 inhibitor.
[0005] Provided herein, in some embodiments, is a method of treating a cancer in a patient in need thereof, said method comprising: administering a composition comprising a heat shock protein 90 (Hsp90) inhibitor; wherein said cancer has been previously determined as comprising a loss of function mutation or a deletion of an HSP90AB 1 or an ataxia telangiectasia mutated (“ATM”) gene. In some embodiments, said loss of function mutation or deletion of said gene reduces an amount or activity of the gene product as compared to a wild-type amount or activity of said the gene product. In some embodiments, said gene product comprises Hsp90p or ATM protein kinase.
[0006] Further provided herein, in some embodiments, is a method of treating a cancer in a patient in need thereof, said method comprising: administering a composition comprising a Hsp90inhibitor; wherein said patient has been previously determined as comprising a reduced amount or function of Hsp90p or ATM protein kinase, respectively. In some embodiments, a loss of function mutation or a deletion of a gene reduces the amount or function of Hsp90p or ATM protein kinase. In some embodiments, epigenetic silencing or translation silencing reduces the amount or function of Hsp90p or ATM protein kinase.
[0007] In some embodiments, said patient has been previously determined as comprising a reduced amount or function of ATM protein kinase as compared to a wild-type amount or function of ATM protein kinase. In some embodiments, said patient has been previously determined as comprising a reduced amount or function of Hsp90p as compared to a wild-type amount or function of Hsp90p.
[0008] In some embodiments, said Hsp90 inhibitor comprises a compound selected from a small molecule drug or a biologic drug. In some embodiments, said biologic drug comprises a compound selected from an antibody, a peptide, a vaccine, or a combination thereof. In some embodiments, said Hsp90 inhibitor comprises a small molecule drug. In some embodiments, said Hsp90 inhibitor is selected from luminespib, ganetespib, onalespib, 17-AAG, SNX-5422, XL-888, BIIB-021, zelavespib, 17-DMAG, BUB-028, DS 2248, retaspimycin, arimoclomol, CTXT-102, SGX-301, RTA 901, T-2143, TAS- 116, PU-AD, or a combination thereof. In some embodiments, said gene is the HSP90AB1 gene. In some embodiments, said cancer comprises lung cancer, colorectal cancer, urinary tract cancer, uterine cancer, stomach cancer, ovarian cancer, or a combination thereof. In some embodiments, said cancer comprises uterine cancer. In some embodiments, the uterine cancer comprises endometrial cancer. In some embodiments, said endometrial cancer is uterine corpus endometrial carcinoma. In some embodiments, the uterine cancer comprises uterine sarcoma. In some embodiments, the uterine sarcoma comprises uterine carcinosarcoma. In some embodiments, said cancer comprises lung cancer. In some embodiments, said lung cancer comprises non-small cell lung cancer. In some embodiments, said cancer comprises colorectal cancer. In some embodiments, said cancer comprises urinary tract cancer. In some embodiments, said urinary tract cancer comprises bladder cancer. In some embodiments, said bladder cancer comprises a carcinoma. In some embodiments, said carcinoma comprises urothelial carcinoma. In some embodiments, said urinary tract cancer comprises kidney cancer. In some embodiments, said cancer comprises stomach cancer. In some embodiments, said cancer comprises ovarian cancer.
[0009] In some embodiments, said gene is the ATM gene. In some embodiments, said cancer comprises lung cancer, colorectal cancer, urinary tract cancer, uterine cancer, breast cancer, stomach cancer, colon cancer, or a combination thereof. In some embodiments, said cancer comprises uterine cancer. In some embodiments, the uterine cancer comprises endometrialcancer. In some embodiments, said endometrial cancer is uterine corpus endometrial carcinoma.
[0010] In some embodiments, the uterine cancer comprises uterine sarcoma. In some embodiments, the uterine sarcoma comprises uterine carcinosarcoma. In some embodiments, said cancer comprises lung cancer. In some embodiments, said lung cancer comprises non-small cell lung cancer. In some embodiments, said cancer comprises colorectal cancer. In some embodiments, said cancer comprises urinary tract cancer. In some embodiments, said urinary tract cancer comprises bladder cancer. In some embodiments, said bladder cancer comprises a carcinoma. In some embodiments, said carcinoma comprises urothelial carcinoma. In some embodiments, said cancer comprises stomach cancer. In some embodiments, said cancer comprises breast cancer. In some embodiments, said cancer comprises colon cancer. In some embodiments, the Hsp90 inhibitor comprises luminespib. In some embodiments, the Hsp90 inhibitor comprises ganetespib. In some embodiments, the Hsp90 inhibitor comprises a second generation Hsp90 inhibitor. In some embodiments, the second generation Hsp90 inhibitor comprises onalespib. In some embodiments, the Hsp90 inhibitor comprises XL-888. In some embodiments, the Hsp90 inhibitor comprises 17-AAG.
[0011] In some embodiments, the Hsp90 inhibitor comprises SNX-5422. In some embodiments, the Hsp90 inhibitor comprises BIIB-021. In some embodiments, the Hsp90 inhibitor comprises zelavespib. In some embodiments, the Hsp90 inhibitor comprises 17-DMAG. In some embodiments, the Hsp90 inhibitor comprises BUB-028. In some embodiments, the Hsp90 inhibitor comprises DS 2248. In some embodiments, the Hsp90 inhibitor comprises retaspimycin. In some embodiments, the Hsp90 inhibitor comprises arimoclomol. In some embodiments, the Hsp90 inhibitor comprises CTXT-102. In some embodiments, the Hsp90 inhibitor comprises SGX-301. In some embodiments, the Hsp90 inhibitor comprises RTA 901. In some embodiments, the Hsp90 inhibitor comprises T-2143. In some embodiments, the Hsp90 inhibitor comprises TAS-116. In some embodiments, the Hsp90 inhibitor comprises PU-AD. In some embodiments, said loss of function or said deletion of said gene is a result of epigenetic silencing or translation silencing.
[0012] In some embodiments, a kit for treating a cancer, comprising: a test for determining a loss of function mutation or a deletion of a gene, and a heat shock protein 90 (“Hsp90”) inhibitor; wherein said gene is a HSP90AB1 gene, or an ataxia telangiectasia mutated (“ATM”) gene. In some embodiments, said Hsp90 inhibitor is selected from luminespib, ganetespib, onalespib, 17-AAG, SNX-5422, XL-888, BIIB-021, zelavespib, 17-DMAG, BIIB-028, DS 2248, retaspimycin, arimoclomol, CTXT-102, SGX-301, RTA 901, T-2143, TAS-116, PU- AD, or a combination thereof. In some embodiments, said cancer comprises lung cancer,colorectal cancer, urinary tract cancer, uterine cancer, stomach cancer, ovarian cancer, breast cancer, colon cancer, or a combination thereof.INCORPORATION BY REFERENCE
[0013] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and / or take precedence over any such contradictory material.BRIEF DESCRIPTION OF DRAWINGS
[0014] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
[0015] FIG. 1 illustrates a Volcano Plot of 182 driver gene mutations tested for synergy with activity of onalespib in KP4 cells.
[0016] FIGs. 2A-2B illustrate the activity of zelavespib (also known as “PU-H71”). FIG. 2A demonstrates the inhibitive activity of zelavespib in KP4 cells with wildtype (“WT”) HSP90AB 1 and with HSP90 AB 1 knocked out. FIG. 2B demonstrates the inhibitive activity of zelavespib in HCT116 cells with wildtype (“WT”) ATM and with ATM knocked out.
[0017] FIG. 3 illustrates the inhibitive activity of SNX-5422 in KP4 cells with wildtype (“WT”) HSP90AB 1 and with HSP90 AB 1 knocked out.
[0018] FIG. 4 illustrates the inhibitive activity of onalespib in H2009 cells with wildtype (“WT”) HSP90AB 1 and with HSP90 AB 1 knocked out.
[0019] FIG. 5 illustrates the inhibitive activity of XL888 in in KP4 cells with wildtype (“WT”) HSP90AB 1 and with HSP90 AB 1 knocked out.
[0020] FIGs. 6A-6B illustrate the activity of luminespib. FIG. 6A demonstrates the inhibitive activity of luminespib in KP4 cells with wildtype (“WT”) HSP90AB1 and with HSP90AB1 knocked out. FIG. 6B demonstrates the inhibitive activity of luminespib in SW780 cells with wildtype (“WT”) ATM and with ATM knocked out.
[0021] FIG. 7 illustrates the inhibitive activity of ganetespib in in SW780 cells with wildtype (“WT”) ATM and with ATM knocked out.
[0022] FIG. 8 illustrates the inhibitive activity of 17-AAG in in SW780 cells with wildtype (“WT”) HSP90AB 1 and with HSP90 AB 1 knocked out.
[0023] FIGs. 9A-9B illustrate the activity of luminespib. FIG. 9A demonstrates the inhibitive activity of BUB-021 in OvCar3 cells with wildtype (“WT”) HSP90AB1 and with HSP90AB1 knocked out. FIG. 9B demonstrates the inhibitive activity of BUB-021 in SW780 cells with wildtype (“WT”) ATM and with ATM knocked out.DETAILED DESCRIPTION OF THE INVENTION
[0024] While various embodiments of the invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions may occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed.
[0025] The present disclosure, in some embodiments, provides for new methods of treatment or prevention of cancers, resulting in unexpectedly superior cancer cell inhibition. The methods provided herein may utilize synthetic lethality to overcome challenges associated with Hsp90 inhibitors, such as the development of resistance to Hsp90 inhibitors, which remains a large problem.
[0026] Synthetic lethality may be described as a phenomenon in which the simultaneous loss of function or deletion (or a combination of both) of two genes together leads to cell death, whereas the loss of function of either gene alone does not lead to cell death. This concept may be used in cancer research as a therapeutic strategy for target identification, where a goal is to identify pairs of genes whose combined inhibition leads to cell death in cancer cells while not resulting in the death of non-cancerous cells. A potentially important concept underlying synthetic lethality may be to target a vulnerability in cancer cells that is not present in normal (e.g., non-cancerous) cells. Since cancer cells already have a mutated gene, a promising approach may be to identify and then pharmacologically target a synthetically lethal partner of one of the mutated genes. However, the identification of synthetic lethal gene pairs and the further identification of a pharmaceutical intervention for use in targeting the synthetically lethal partner remains a significant challenge.I. Methods of Treating Cancer
[0027] In some embodiments, the present disclosure provides methods and kits for treating a cancer through the use of synthetic lethality. The methods and kits provided herein may utilize synthetic lethality in cancers comprising a loss of function mutation or a deletion of theHSP90AB1 gene or an ataxia telangiectasia mutated (“ATM”) gene by administration of a Hsp90 inhibitor. In some embodiments, the method comprises treating a cancer comprising a loss of function mutation in a HSP90AB 1 gene or a deletion of a HSP90AB 1 gene. In some embodiments, the method comprises treating a cancer comprising a loss of function mutation in an ATM gene or a deletion of an ATM gene. In some embodiments, the loss of function mutation is in a HSP90AB1 gene. In some embodiments, the deletion is of the HSP90AB1 gene. In some embodiments, the loss of function mutation is in an ATM gene. In some embodiments, the deletion is of the ATM gene.
[0028] In some embodiments, said loss of function mutation or deletion of said gene reduces an amount or activity of a gene product (e.g., as compared to a wild-type amount or activity of said the gene product, or as compared to a non-cancerous corresponding cell). In some embodiments, said gene product comprises Hsp90p or ATM protein kinase. The reduced amount or activity of Hsp90p may be a result of a loss of function mutation or deletion of a HSP90AB1 gene. The reduced amount or activity of ATM protein kinase may be a result of a loss of function mutation of an ATM gene.
[0029] Further provided herein, in some embodiments, are methods of treating a cancer in a patient in need thereof, said method comprising: administering a composition comprising a Hsp90 inhibitor; wherein said patient has been previously determined as comprising a reduced amount or function of Hsp90p or ATM protein kinase, respectively. In some embodiments, a loss of function mutation or a deletion of a gene reduces the amount or function of Hsp90p or ATM protein kinase. In some embodiments, the reduced amount or function of Hsp90p or ATM protein kinase is not a result of pharmacological inhibition. In some embodiments, said method further comprises determining if the subject (e.g., a cancer cell or tumor of the subject) has a reduced amount or function of Hsp90p or ATM protein kinase. In some embodiments, epigenetic silencing or translation silencing reduces the amount or function of Hsp90p or ATM protein kinase. The reduced amount or activity of Hsp90p may be a result of a loss of function mutation or deletion of a HSP90AB 1 gene. The reduced amount or activity of ATM protein kinase may be a result of a loss of function mutation of an ATM gene. In some embodiments, said method further comprises determining if the subject (e.g., a cancer cell or tumor of the subject) has a loss of function mutation or deletion of a HSP90AB1 gene or an ATM gene.
[0030] In some embodiments, said patient has been previously determined as comprising a reduced amount or function of ATM protein kinase as compared to a wild-type amount or function of ATM protein kinase. In some embodiments, said patient has been previously determined as comprising a reduced amount or function of Hsp90p as compared to a wild-type amount orfunction of Hsp90p. In some embodiments, said Hsp90 inhibitor comprises a compound selected from a small molecule drug or a biologic drug. In some embodiments, said biologic drug comprises a compound selected from an antibody, a peptide, a vaccine, or a combination thereof.
[0031] In some embodiments, said Hsp90 inhibitor comprises a small molecule drug. In some embodiments, said Hsp90 inhibitor is selected from luminespib, ganetespib, onalespib, 17- AAG, SNX-5422, XL-888, BIIB-021, zelavespib, 17-DMAG, BIIB-028, DS 2248, retaspimycin, arimoclomol, CTXT-102, SGX-301, RTA 901, T-2143, or a combination thereof. In some embodiments, said Hsp90 inhibitor is selected from HSP 990, icapamespib, KW 2478, LAM-003, locnartecan, MPC 3100, TQB 3474, WP-1303, geldanamycin, IPI-493, MPC-3100, Debio0932, VER-82576, or any combination thereof. In some embodiments, said Hsp90 inhibitor is PU-AD. In some embodiments the Hsp90 inhibitor comprises a purine- based Hsp90 inhibitor. In some embodiments, the purine-based Hsp90 inhibitor comprises zelavespib, icapamespib, MPC-310, or a combination thereof. In some embodiments, the Hsp90 inhibitor comprises a resorcinol-based HSP90 inhibitor. In some embodiments, the resorcinol -based HSP90 inhibitor comprises luminespib, onalespib, ganetespib, or a combination thereof. In some embodiments, the Hsp90 inhibitor comprises a geldanamycin analogue. In some embodiments, the geldanamycin analogue comprises 17-AAG, 17-DMAG,
[0032] Provided herein, in some embodiments, are methods of treating a cancer in a patient in need thereof. In some embodiments, the method comprises administering (e.g., a therapeutically effective amount of) a composition comprising a Hsp90 inhibitor to a patient having a cancer. In some embodiments, the Hsp90 inhibitor is a Hsp90 alpha inhibitor. In some embodiments, the Hsp90 inhibitor is a Hsp90 beta inhibitor. In some embodiments, the cancer comprises a loss of function mutation or a deletion of a gene (e.g., HSP90AB1 or ATM gene). In some embodiments, the cancer has been determined (e.g., previously determined) as comprising a loss of function mutation in a gene or a deletion of a gene (e.g., HSP90AB1 or ATM gene). In some embodiments, said patient comprises a reduced amount (i.e., number) of Hsp90p or ATM protein kinase or function of Hsp90p or ATM protein kinase. In some embodiments, said reduced amount of Hsp90p or ATM protein kinase or function of Hsp90p or ATM protein kinase is in a cancer cell of the subject.
[0033] In some embodiments, said cancer comprises lung cancer, colorectal cancer, urinary tract cancer, uterine cancer, stomach cancer, ovarian cancer, or a combination thereof. In some embodiments, said cancer comprises uterine cancer. In some embodiments, the uterine cancer comprises endometrial cancer. In some embodiments, said endometrial cancer is uterine corpus endometrial carcinoma. In some embodiments, the uterine cancer comprises uterinesarcoma. In some embodiments, the uterine sarcoma comprises uterine carcinosarcoma. In some embodiments, said cancer comprises lung cancer. In some embodiments, said lung cancer comprises non-small cell lung cancer. In some embodiments, said cancer comprises colorectal cancer. In some embodiments, said cancer comprises urinary tract cancer. In some embodiments, said urinary tract cancer comprises bladder cancer. In some embodiments, said bladder cancer comprises a carcinoma. In some embodiments, said carcinoma comprises urothelial carcinoma. In some embodiments, said urinary tract cancer comprises kidney cancer. In some embodiments, said cancer comprises stomach cancer. In some embodiments, said cancer comprises ovarian cancer.
[0034] In some embodiments, the method of treating a cancer in a patient in need thereof comprises determining whether the patient has a mutation (e.g., LOF mutation) or deletion of a HSP90AB1 or an ataxia telangiectasia mutated (“ATM”) gene (e.g., by obtaining or having obtained a biological sample form the patient), and if the patient has the mutation or deletion of the HSP90AB1 or ATM gene, then administering a Hsp90 inhibitor. In some embodiments, said method further comprises performing or having performed a test (e.g., assay) on the biological sample to determine if the patient has the mutation (e.g., LOF mutation) or deletion of the HSP90AB1 or ATM gene.
[0035] In some embodiments, the method of treating a cancer in a patient in need thereof comprises determining whether the patient has a reduced amount or function of Hsp90p or ATM protein kinase (e.g., by obtaining or having obtained a biological sample form the patient), and if the patient has the reduced amount or function of Hsp90p or ATM protein kinase, then administering a Hsp90 inhibitor. In some embodiments, said method further comprises performing or having performed a test (e.g., assay) on the biological sample to determine if the patient has the a reduced amount or function of Hsp90p or ATM protein kinase. In some embodiments, the reduced amount or function of PI3K-alpha is not a result of pharmacological inhibition. a. Hsp90 Inhibitors
[0036] Hsp90 may be an important chaperone protein that functions to maintain the correct folding of client proteins. It may regulate protein folding and degradation, several cell signaling pathways, cell proliferation and survival, and cell apoptosis via interacting with co-chaperones and client proteins. Hsp90 consists of three distinct domains: i) The NTD, which may include an ATP binding site and the client protein binding site; ii) an MD that may be responsible for the hydrolysis of ATP to ADP; and iii) a CTD, which may be comprised of a protein dimerization site and a calmodulin-binding site; there may also a linker domain connecting theNTD to the MD, contributing to the maintenance of the functions, interactions, and adaptability of the Hsp90 chaperone. The NTD, which may also be referred to as the nucleotide-binding site, may be important for the affinity between client proteins and Hsp90, and for the chaperone cycle, due to the presence of the binding site for ATP which may be important for the Hsp90 ATPase activity. Thus, the NTD may be considered an important target in the development of inhibitors. The CTD may primarily be involved in the dimerization of Hsp90. There may also be an ATP binding site that only opens when the ATP- binding site in the NTD is unavailable, making the C-terminal an allosteric regulator of the N- terminal ATPase activity. There may be special motifs, including MEEVD or KDEL on CTD, which differ according to the different isoform types and the cellular localization.
[0037] Dimerization may be necessary for Hsp90 to function properly in cancer cells. Hsp90ATPase activity and the cycling between the closed and open conformations may be important in this process. Despite the different locations in cells, all the isoforms of Hsp90 may act in a similar manner in the ATPase cycle. Hsp90 may exist as flexible homodimers, being predominantly present in an open V-shaped conformation with N-terminus separating, termed the ‘open conformation’. In the open conformation, the binding sites in the N-terminus may be available to client proteins. ATP may translocate over the specific sites in the NTD and induces the N- terminus to attach to the corresponding domain of the other homodimer, leading to closure of the V-shaped conformation. The dimerized N-domains may be associated with the M- domains, forming a twisted and compacted conformation, which is termed ‘closed conformation’ . In the closed conformation, client proteins may be confined within the chaperone. Following ATP hydrolysis to ADP and PPi and release from the binding pocket, the NTDs may dissociate, and Hsp90 may return to its open conformation.
[0038] The Hsp90 family may include four isoforms that are present at different locations in a cell. HSP90a and HSP90P may be present in the cytoplasm and the nucleus, GRP94 may be present in the endoplasmic reticulum, and TRAP-1 may be primarily located in the mitochondrion, also potentially being present in the endoplasmic reticulum. HSP90a and HSP90P are widely expressed isoforms and may be primarily located in the cytoplasm. They may be involved in cell signaling, energy metabolism and cell viability. Additionally, extracellular-secreted Hsp90a (eHsp90a) has been demonstrated to play crucial roles in the invasion and migration of several types of cancer in vitro and in vivo. GRP94 may function as a ‘quality supervisor’ of secreted proteins and membrane proteins. GRP94 may recognize and binds to misfolded proteins, attempt to correct them, and prevent their degradation in the cytoplasm. The inhibition of GRP94 may result in the accumulation of misfolded proteins, which may translocate to the cytoplasm and are marked for degradation. TRAP-1 may beimportant for mitochondrial homeostasis and has may be involved in regulating the mitochondrial redox state and curbing energy metabolism. All four isoforms may share a high degree of sequence similarity in the N-terminus, thus the ATP binding sites on the N-terminus may be important targeting spots to disrupt molecular chaperone function.
[0039] Hsp90 may be a key mediator of >200 proteins, termed ‘Hsp90 client proteins’. Hsp90 may facilitate protein-protein interactions and may be involved in cell signaling and the responses to stress. Cancer cells may use this mechanism to protect the mutated and overexpressed oncoproteins from misfolding and being degraded to ensure their survival and proliferation. Several Hsp90 client proteins may participate in signaling and other vital pathways that are important for malignancy. These client proteins may include receptor tyrosine kinases (HER2, EGFR, IGF-1R and MET), signaling proteins (AKT and SRC), transcription factors (HIF-1 and TP53) and cell cycle regulatory proteins (CDK4 and CDK6). There may be several cochaperones, including p50 / Cdc37, Hsp90 -organizing protein (HOP / Stil, p23, Ahal and Hsp70), and a variety of immunophilins that require Hsp90 to function. The Hsp90 chaperone mechanisms and Hsp90 -client interactions may be involved in establishing the acquired capabilities of cancer cells by regulating Hsp90 -dependent signal transduction. Thus, Hsp90 inhibitors may effectively suppress the tumor-promoting signaling pathways and interrupt the functions of Hsp90 in tumor cells.
[0040] Hsp90 chaperone mechanisms in cancer cells may differ considerably from those in normal cells. Firstly, in cancer cells, the rapid proliferation rate and reduced control in protein synthesis quality may result in increased and constant cellular stress. In response to this situation, heat shock factor 1 (HSF1) may be released and form a trimer. The trimer may translocate to the nucleus and upregulates Hsp90 expression. Increased levels of Hsp90 may improve the chances of cell survival and in maintaining function during tumorigenesis. Studies have demonstrated that the expression of Hsp90 may be 2- to 10-fold higher in cancer cells than in normal cells, and the overexpression of Hsp90 may be found in numerous tumor cells including breast, lung, colorectal, ovarian, endometrial, esophageal, bone, urinary, and prostate cancer. The high expression of Hsp90 may be associated with a poor prognosis in clinical treatment. Hsp90 expression may be a determining factor in the survival outcomes in hormone and protein kinase-dependent breast cancer. A study revealed a potential association between a high level of Hsp90 expression and a less favorable response to anti -neoplastic treatment. In another study, biostatisticians analyzed Hsp90 expression levels from >4,000 breast cancer patients from 23 databases and overall survival data from >1,000 patients. Upregulation of Hsp90 and HSF1 was observed in breast cancer and may result in a more aggressive profile of the cancer and a poorer prognosis.
[0041] Hsp90-client interactions and post-translational modifications may also differ between tumor and healthy cells. Mutated oncoproteins expressed in cancer cells may be involved in the uncontrolled growth and proliferation of cancer cells. The majority of these oncoproteins may also be client proteins of Hsp90. Of note, >400 client proteins have been discovered to be involved in cell signaling by binding to Hsp90. Additionally, post-translational modifications may regulate HSP90-client interactions. HSP90 inhibitors may display a high affinity to Hsp90 in tumor cells. Inhibitors may interrupt the function of HSP90 in cancer cells, while at the same dose, Hsp90 is not inhibited in normal cells. In fact, HSP90 in cancer cells may exist as a multi chaperone complex. Complexes may promote the ATPase activity of Hsp90 and promote the affinity of Hsp90 to its inhibitor 100-fold. There may also be biologically distinct HSP90 complexes present in tumor cells. Those Hsp90 functions may differ from its physiological roles and may help ensure tumor cell survival, by interacting with oncogenic proteins; however, the majority of Hsp90 present in tumor cells may be similar to that in normal cells. Notably, the higher the ATPase activity of Hsp90 in tumors, the better the affinity is to HSP90 inhibitors, which is evidence supporting that transformation and malignancy do not solely center around overexpression of Hsp90.
[0042] Cell surface Hsp90 expression may be considerably higher in tumor cells than in normal cells, highlighting Hsp90 as a prospective target in anti -neoplastic treatment. To adapt to the reduced ATP-extracellular environment, extracellular Hsp90 may function independently of ATP. Due to the consistent environmental stress in tumor cells, HSP90 may be secreted consecutively, while Hsp90 in healthy cells is secreted only under conditions of stress. Blocking or neutralizing the secretion of Hsp90 may inhibit the invasion and migration of cancer. A clinical study revealed that plasma concentrations of Hsp90 may be positively associated with tumor malignancy in cancer patients. The inhibition of extracellular Hsp90 may be an attractive approach for preventing malignant tumor progression. Significant attention has been paid to discovering inhibitors targeting the NTD of Hsp90 in the last few decades. At present, there are 18 inhibitors of Hsp90 that have been designed and have entered clinical trials.
[0043] Provided below are non-limiting descriptions of a few exemplary Hsp90 inhibitors. i. Luminespib
[0044] Luminespib (which may also be referred to as AUY-922, NVP-AUY922, or VER-52296) may be a highly potent HSP90 inhibitor. For HSP90a / p, luminespib has demonstrated an IC50 of 13 nM / 21 nM, respectively, in cell-free assays, with weaker potency against the HSP90 family members GRP94 and TRAP-1. Luminespib may also exhibit the tightest binding ofany small-molecule HSP90 ligand. Luminespib may effectively downregulate and destabilize the IGF-1RP protein and results in growth inhibition, autophagy and apoptosis.Luminespib
[0045] Provided herein, in some embodiments, are methods of treating a cancer in a patient in need thereof, said method comprising administering luminespib, wherein said cancer has been previously determined as comprising a loss of function mutation or a deletion of a gene. Further provided herein in some embodiments, are methods of treating a cancer in a patient in need thereof, said method comprising administering Luminespib, wherein said patient has been previously determined as comprising a reduced amount or function of HSP90 as compared to a wild-type amount or function of HSP90. For more information on Luminespib, see: Preparation of isoxazoles as inhibitors of heat shock proteins, W02004072051 Al; and 4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer, Brough et. al., Journal of Medicinal Chemistry (2008), 51(2), 196-218, which are herein by reference in their entirety. ii. Ganetespib
[0046] Ganetespib (which may also be referred to as STA-9090) is an HSP90 inhibitor that may be the active metabolite of STA-1474. Ganetespib has demonstrated an IC50 of 4 nM in OSA 8 cells, and may induce apoptosis of OSA cells without affecting normal osteoblasts. Ganetespib may exhibit potent in vitro cytotoxicity in a range of solid and hematologic tumor cell lines and may induce the degradation of known Hsp90 client proteins. Ganetespib may be a potent HSP90 inhibitor, and has been shown to kill canine tumor cell lines in vitro. Ganetespib may possess beneficial JAK / STAT inhibitory activity in terms of potency or duration of response.Ganetespib
[0047] When administered, ganetespib may accumulate in tumors more than normal tissues. Ganetespib has demonstrated beneficial in vivo efficacy without increased toxicity. Ganetespib has been shown to inhibit proliferation and induce apoptosis in parallel with EGFR depletion in NCI-H1975 xenografts. Ganetespib has demonstrated potent antitumor efficacy in solid and hematologic xenograft models of oncogene addiction, as evidenced by significant growth inhibition and / or regressions. For more information on Ganetespib, see: Preparation of triazoles as Hsp90 inhibitors for treating cancer, W02006055760 Al; and Experimental and Structural Testing Module to Analyze Paralogue-Specificity and Affinity in the Hsp90 Inhibitors Series, Taldone, et al., Journal of Medicinal Chemistry (2013), 56(17), 6803-6818, which are herein by reference in their entirety. iii. Onalespib
[0048] Onalespib (which may also be referred to as AT13387) is an Hsp90 inhibitor that may demonstrate selective and potent inhibition of Hsp90. Onalespib has demonstrated anIC50 of 18 nM in A375 cells and may display a long duration of anti -tumor activity. Onalespib has demonstrated a binding Kd of 0.7 nM. Onalespib has demonstrated a mean stoichiometry of binding of 1.03. When tested, CDK 1, CDK 2, CDK4, FGFR3, PKB-b, JAK2, VEGFR2, PDGFRP and Aurora B kinases were significantly inhibited at concentrations below 30 pM. Onalespib may be a potent inhibitor of the proliferation and survival of many different cell lines (such as MES-SA cell line) from a variety of different tumor types. Across a panel of 30 tumor cell lines, AT 13387 has demonstrated that it may potently inhibit cell proliferation with GI50 values in the range 13-260 nM. Onalespib may inhibit proliferation of the non- tumorigenic human prostate epithelial cell line PNT2 with a GI50 value of 480 nM.Onalespib
[0049] For more information on Onalespib, see: W02006109085 Al, and Discovery of (2,4- Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-l-ylmethyl)-l,3-dihydroisoindol-2- yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design, Woodhead, et al Journal of Medicinal Chemistry (2010), 53(16), 5956- 5969, which are herein by reference in their entirety.iv. Tanespimycin
[0050] Tanespimycin (which may also be referred to as 17-AAG) is an Hsp90 inhibitor that may demonstrate selective and potent inhibition of Hsp90 . Tanespimycin has demonstrated an IC50 of 5 nM, having a 100-fold higher binding affinity for tumor cell derived HSP90 than normal cell derived HSP90. Tanespimycin may deplete cellular STK38 / NDR1 and reduce STK38 kinase activity. Tanespimycin may also downregulate the stk38 gene expression. Tanespimycin may cause the degradation of HER2, Akt, and both mutant and wild-type AR and the retinoblastoma-dependent G1 growth arrest of prostate cancer cells. Tanespimycin has been shown to inhibit prostate cancer cell lines with IC50s ranged from 25-45 nM (LNCaP, 25 nM; LAPC-4, 40 nM; DU-145, 45 nM; and PC-3, 25 nM). Tanespimycin (0.1-1 M) may induce a nearly complete loss of ErbB2 on ErbB2-overexpressing breast cancer cells. Tanespimycin may inhibit cell growth and may induce G2 / M cell cycle arrest and apoptosis in CCA cells together with the down-regulation of Bcl-2, Survivin and Cyclin B l, and the upregulation of cl eaved PARP.Tanespimycin
[0051] Tanespimycin may cause a dose-dependent decline in AR, HER2, and Akt expression in prostate cancer xenografts. Tanespimycin treatment has been demonstrated to induce AR, HER2, and Akt degradation, which may result in the dose-dependent inhibition of androgendependent and -independent prostate cancer xenograft growth without toxicity. v. PF-04929113
[0052] PF-04929113 (which may also be referred to as SNX-5422) is an Hsp90 inhibitor that may demonstrate selective and potent inhibition of Hsp90. PF-04929113 has demonstrated a Kd of 41 nM and Her-2 degradation with an IC50 of 37 nM. PF-04929113, may convert to SNX- 2122, which may be the active Hsp90 inhibitor form. PF-04929113 has exhibited potent effects on Her-2 stability and has caused expected up-regulation of Hsp70. PF-04929113 demonstrated potent antiproliferative activity against a broad range of cancer cell types, e.g. PF-04929113 has demonstrated antiproliferative activity against the following cells: MCF-7 (IC50=16 nM), SW620 (IC50=19 nM), K562 (IC50=23 nM), SK-MEL-5 (IC50=25 nM), and A375 (IC50=51 nM).PF -04929113
[0053] PF-04929113 may inhibit human MM cell growth in vivo. Immuno-histochemical analysis showed that PF-04929113 significantly inhibits p-ERK and p-Akt in treated mice. Furthermore, PF-04929113 treatment significantly decreased the percentage of CD31+ cells and MVD, consistent with an inhibitory effect on angiogenesis in vivo. Administration of PF- 04929113 significantly delayed castrate-resistant LNCaP tumor growth and prolonged cancer specific survival. Immuno-histochemical analysis indicated increased SP70 expression, and decreased Ki67, Akt, and AR expression, after treatment with PF-04929113. Inhibition of tumor progression by PF-04929113 may result from a combination of decreased proliferative (reduced Ki67 and Akt expression) or increased apoptosis (increased ApopTag staining) rates. vi. XL888
[0054] XL888 is a heat shock protein-90 (HSP90) inhibitor. XL888 has demonstrated an IC50 of 24 nM. Treatment with XL888 has led to dose dependent decreases in the growth of all the cell lines with no significant difference in IC50 values observed between the naive and resistance pairs of cell lines (t=0.25, p=0.82). Treatment of all of the vemurafenib resistant cell lines with XL888 (300 nM) induced high levels (>66%) of apoptosis, caspase-3 cleavage and loss of mitochondrial membrane potential (TMRM) in tested cell lines. Treatment of cell lines that are naive, intrinsically resistant and with acquired vemurafenib resistance with XL888 (300 nM) led to robust time-dependent increases in the expression of HSP70 isoform 1 (HSP71).XL888
[0055] Treatment of the established M245 tumors with XL888 (125 mg / kg 3* week) led to a significant slowing of tumor growth (P=0.017) without any effect upon animal weights. Analysis of xenograft specimens by LC-MRM showed a marked increase in intratumoral HSP70 expression following XL888 treatment. It is noted that the XL888 was well tolerated by the mice, with no significant alterations in body weigh observed over the study period. LC-MRM mediated analysis of xenograft samples following 15-days of XL888 treatment showed a robust (8.6-fold) increase in intratumoral HSP70 expression compared to controls. vii. BIIB021
[0056] BIIB021 (which may also be referred to as CNF2024) is an Hsp 90 inhibitor that may be orally active. BIIB021 may be a fully synthetic inhibitor of HSP90. BIIB021 has demonstrated a Ki and an EC50 of 1.7 nM and 38 nM, respectively. BIIB021 may bind in the ATP -binding pocket of Hsp90, interfere with Hsp90 chaperone function, and result in client protein degradation and tumor growth inhibition. BIIB021 inhibited tumor cell (BT474, MCF- 7, N87, HT29, H1650, H1299, H69 and H82) proliferation with an IC50 from 0.06-0.31 pM. BIIB021 may induce the degradation of Hsp90 client proteins including HER-2, Akt, and Raf- 1 and up-regulated expression of the heat shock proteins Hsp70 and Hsp27.
[0057] BHB021 inhibited Hodgkin's lymphoma cells (KM-H2, L428, L540, L540cy, L591, L1236 and DEV) with IC50 from 0.24-0.8 pM. BIIB021 showed low activity in lymphocytes from healthy individuals. BIIB021 inhibited the constitutive activity of NF-KB despite defective IKB. BIIB021 may induce the expression of ligands for the activating NK cell receptor NKG2D on Hodgkin's lymphoma cells resulting in an increased susceptibility to NK cell- mediated killing. BIIB021 enhanced the in vitro radiosensitivity of HNSCCA cell lines (UM1 IB and JHU12) with a corresponding reduction in the expression of key radioresponsive proteins, increases apoptotic cells and enhances G2 arrest. BIIB021 may possess superior activity against adrenocortical carcinoma H295R. The cytotoxic activity of BIIB021 may not be influenced by loss of NQO1 or Bcl-2 overexpression, molecular lesions that do not prevent client loss but are nonetheless associated with reduced cell killing by 17-AAG. BIIB021 was also active in 17-AAG resistant cell lines (NIH-H69, MES SA Dx5, NCI-ADR-RES, Nalm6).BHB021
[0058] Oral administration of BIIB021 led to tumor growth inhibition in many tumor xenograft models including N87, BT474, CWR22, U87, SKOV3 and Panc-1. BIIB021 effectively inhibited growth of L540cy tumor. Furthermore, BIIB021 significantly enhanced antitumor growth effect of radiation in JHU12 xenograft.viii. Zelavespib
[0059] Zelavespib (which may also be referred to as PU-H71, NSC 750424) is a Hsp 90 inhibitor that may be a potent and selective inhibitor of Hsp 90. Zelavespib may be an oral synthetic purine-based Hsp90 inhibitor, with . Zelavespib demonstrated an IC50 of 51 nM. Zelavespib potently suppressed the growth of triple-negative breast cancers (TNBC) cell lines MDA-MB- 468, MDA-MB-231, and HCC-1806 with IC50 of 65, 140 and 87 nM, respectively. Zelavespib killed 80%, 65%, and 80% of the initial population of MDA-MB-468, MDA-MB- 231, and HCC-1806 cells, respectively. Zelavespib induced a dose-dependent degradation or inactivation of tumor driving molecules, including EGFR, IGF1R, HER3, c-Kit, Raf-land Akt. Treatment for 24 h with PU-H71, has been shown to augment the percent of cells in G2- M phase of MDA-MB-468 to 69%, mediated by reduction in CDK1 and Chkl expression. Zelavespib may induce apoptosis in TNBC in part by inactivation and downregulation of Akt and Bcl-xL. Zelavespib has led to a proteasome-mediated reduction in IRAK-1 and TBK1 levels, resulting in approximately 84% and 90% reduction in NF-KB activity in MDA-MB- 231 cells treated with 0.5 and IpM PU-H71, respectively. Zelavespib markedly contained MDA-MB-23 1 cell invasion, with 90% suppression at 1 pM. Zelavespib has generated endoplasmic reticulum (ER) stress and activated the Unfolded Protein Response (UPR) as evidenced by XBP1 mRNA splicing (2.3-fold) and up-regulation of Grp94 (3.7-fold), Grp78 (4.9-fold), and CHOP (48-fold) protein expression and ATF4 (1.8-fold) mRNA expression. Zelavespib may induce the mitochondrial pathway of apoptosis in HeLa cells, mediated by caspase but not calpain activation. In response to PU-H71 -induced ER stress, apoptosis may be triggered in melanoma, cervix, colon, liver and lung cancer cells, but not in normal human fibroblasts. Zelavespib may induce apoptosis and overcome the resistance conferred by Bcl-2. Zelavespib significantly reduced NOS2 activity (60% reduction) and expression in LI (1 pg / mL LPS and 5 ng / mL IFN y)-stimulated astrocytes via inhibiting NF-KB element activation. Zelavespib displayed similar effects on microglial cells as on astrocytes, with 50 nM PU-H71 needed to significantly reduce the LPS dependent nitrite release. In some embodiments the Hsp90 inhibitor comprises a purine-scaffold Hsp90 inhibitor. In some embodiments, the purine-scaffold Hsp90 inhibitor comprises zelavespib.Zelavespibb. HSP90AB1 Gene
[0060] The HSP90AB1 gene, also known as Heat Shock Protein 90 Alpha Family Class B Member 1, may encode for a chaperone protein called Hsp90p. This protein is a member of the heat shock protein family, which may play an important role in regulating protein folding, stability, and degradation in the cell. Hsp90p may be involved in various cellular processes, including signal transduction, cell cycle control, DNA repair, and protein degradation. It has also been shown to interact with a wide range of client proteins, including kinases, transcription factors, and steroid hormone receptors. Mutations in the HSP90AB1 gene have been linked to various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Inhibitors of Hsp90p have also been developed as potential therapeutics for cancer and other diseases. The Hsp90p protein may play a critical role in regulating the folding, stability, and degradation of client proteins, many of which are involved in cancer progression. Inhibiting Hsp90p may potentially lead to the degradation of these oncogenic client proteins, which may inhibit tumor growth and survival.
[0061] Although Hsp90 inhibitors provide a promising area of research in the study of cancer, the development of resistance to Hsp90 inhibitors remains a significant challenge. Many of the relevant compounds have been unsuccessful in patients due to high levels of toxicity or their inability to downregulate the Hsp90 pathway. Studies have shown that cancers may disregard the downregulation of the HSP90 pathway by either maintaining or re-establishing activation of the targeted pathway or by inducing alternate signaling pathways. In fact, a number of studies have shown that short-term treatments with a HSP90 inhibitor may result in the activation of feedback loops that subsequently decrease overall response rates, and that chronic administration of these therapies may result in the establishment of a reservoir of slow cycling cells that eventually may acquire resistance-conferring genetic mutations. Accordingly, there is a need to identify, and research means for overcoming resistance to HSP90 inhibitors.
[0062] One potential strategy to overcome challenges associated with cancers associated with HSP90AB1 gene mutations or deletions may be through synthetic lethality. Since many cancer cells already have a mutated HSP90AB1 gene, a promising approach may be to identify and then pharmacologically target a synthetically lethal partner of one of the mutated HSP90AB1 gene or deleted HSP90AB1 gene. Surprisingly, the current inventors have discovered that cancer cells possessing a HSP90AB1 loss-of-function mutation are unexpectedly susceptible to inhibition of HSP90 activity. As such, in some embodiments, the methods of treating a cancer provided herein may comprise treating a cancer comprising a loss of function mutation in a HSP90AB1 gene or a deletion of a HSP90AB1 gene. A HSP90AB1mutation is a genetic alteration in the HSP90AB1 gene that may result in a change in the protein sequence.
[0063] HSP90AB1 gene mutations have been identified in a variety of human cancers, including, but not limited to, non small cell lung cancer, colorectal cancer, bladder / urinary tract cancer, kidney cancer, uterine / endometrial cancer, stomach cancer, and ovarian cancer.
[0064] In some embodiments, the mutation (e.g., loss of function mutation) or the deletion is in a HSP90AB1 gene. In some embodiments, the mutation is in a HSP90AB1 gene. In some cases, the mutation of a HSP90AB1 gene results in development of a cancer. In some embodiments, the mutation is a loss of function mutation. In some embodiments, the deletion is of a HSP90AB1 gene.
[0065] In some embodiments, said cancer comprises a loss of function mutation in the gene. In some embodiments, the loss of function mutation is in a HSP90AB1 gene. As used herein, a loss of function mutation may refer to a mutation in a gene that results in lower function of the gene, a lower function of a product of the gene, or a lower production of a product of the gene (e.g., an amount of protein produced by the gene (e.g., HSP90-beta)).
[0066] In some embodiments, said cancer comprises a deletion of a gene. In some embodiments, said deletion is of a HSP90AB1 gene. In some embodiments, the deletion of the HSP90AB1 gene results in the cancer of the patient or is a result of the cancer.
[0067] In some embodiments, the cancer comprises a reduced amount or activity HSP90-beta. The reduced amount or activity of HSP90- beta may be due to the mutation or deletion of the Hsp90 gene. The reduced amount or activity of HSP90- beta may be due to epigenetic silencing or translation silencing.
[0068] In some embodiments, the reduced amount or activity of HSP90- beta comes from epigenetic silencing. In some embodiments, the reduced amount or activity of HSP90- beta comes from epigenetic silencing.
[0069] Epigenetic gene silencing may refer to nonmutational gene inactivation that may be faithfully propagated from precursor cells to clones of daughter cells. Alterations in epigenetic gene regulation may associated with human disease, such as cancer. For example, there are potentially connections between DNA methylation and histone methylation. Mutations in genes encoding DNA methyltransferases and proteins that bind methylated cytosine residues may cause changes in gene expression and alterations in the patterns of DNA methylation. These changes may be associated with cancer. Gene silencing may also be controlled through histone methylation. In some embodiments, the reduced amount or activity of HSP90-beta comes from translational silencing. Translational silencing may refer to the suppression or inhibition of protein synthesis from mRNA molecules. It may be a regulatory mechanism thatoccurs after transcription and mRNA processing, and it can control gene expression at the level of protein production. c. ATM gene
[0070] The Ataxia Telangiectasia Mutated gene, commonly referred to as ATM, is a tumor suppressor gene that may play a critical role in the DNA damage response (DDR) pathway. ATM gene may encode an ATM protein kinase that is activated in response to DNA damage, particularly double-strand breaks (DSBs). Upon activation, ATM may phosphorylate numerous downstream targets involved in the DDR pathway, leading to cell cycle arrest, DNA repair, or apoptosis. ATM may also play a crucial role in maintaining genomic stability by preventing the propagation of DNA damage-induced mutations. Mutations in the ATM gene may lead to the development of Ataxia Telangiectasia (A-T), a rare autosomal recessive disorder characterized by progressive cerebellar degeneration, immune deficiency, and increased cancer susceptibility. A-T patients have impaired DDR due to the loss of functional ATM protein, leading to genomic instability and a higher risk of cancer. In addition to A-T, ATM mutations have also been linked to an increased risk of breast cancer and other cancers.
[0071] In some embodiments, the methods of treating a cancer provided herein comprise treating a cancer comprising a loss of function mutation in a ATM gene or a deletion of a ATM gene. A ATM mutation is a genetic alteration in the ATM gene that may result in a change in the protein sequence.
[0072] ATM gene mutations have been identified in a variety of human cancers, including, but not limited to, colorectal cancer, bladder / urinary tract cancer, kidney cancer, uterine / endometrial cancer, breast cancer, and stomach cancer.
[0073] In some embodiments, the mutation (e.g., loss of function mutation) or the deletion is in a ATM gene. In some embodiments, the mutation is in an ATM gene. In some cases, the mutation of an ATM gene results in development of a cancer. In some embodiments, the mutation is a loss of function mutation. In some embodiments, the deletion is of an ATM gene.
[0074] In some embodiments, said cancer comprises a loss of function mutation in the gene. In some embodiments, the loss of function mutation is in an ATM gene. As used herein, a loss of function mutation may refer to a mutation in a gene that results in lower function of the gene, a lower function of a product of the gene, or a lower production of a product of the gene (e.g., an amount of protein produced by the gene).
[0075] In some embodiments, said cancer comprises a deletion of a gene. In some embodiments, said deletion is of an ATM gene. In some embodiments, the deletion of the ATM gene results in the cancer of the patient or is a result of the cancer.
[0076] In some embodiments, the cancer comprises a reduced amount or activity of ATM protein kinase. The reduced amount or activity of ATM protein kinase may be due to the mutation or deletion of the ATM gene. The reduced amount or activity of ATM protein kinase may be due to epigenetic silencing or translation silencing.
[0077] In some embodiments, the reduced amount or activity of ATM protein kinase comes from epigenetic silencing. In some embodiments, the reduced amount or activity of ATM protein kinase comes from translational silencing. d. Types of Cancer
[0078] A loss of function mutation or deletion of a HSP90AB1 or an ATM gene may result in a cancer or may exacerbate the severity or metastasis of the cancer. The methods provided herein may be useful in the treatment of a cancer, such as a cancer comprising a mutation (e.g., a loss of function mutation) in or a deletion of a HSP90AB1 or an ATM gene
[0079] Evidence for a HSP90AB1 or an ATM loss of function mutation may be manifested as reduced Hsp90 signaling. Evidence has demonstrated that a loss of function in a HSP90AB1 gene is particularly strong in lung cancer, colorectal cancer, urinary tract cancer, uterine cancer, stomach cancer, and ovarian cancer. A loss of function in an ATM gene may be present in cancers such as lung cancer, colorectal cancer, urinary tract cancer, uterine cancer, breast cancer, stomach cancer, and colon cancer.
[0080] In some embodiments, the cancer to be treated comprises bladder cancer, breast cancer, urothelial cancer, rectal cancer, thymus cancer, sarcoma, or a combination thereof. In some embodiments, the cancer comprises bladder cancer. In some embodiments, the cancer comprises rectal cancer. In some embodiments, the cancer comprises breast cancer. In some embodiments, the cancer comprises a sarcoma. In some embodiments, the cancer comprises thymus cancer.
[0081] In some embodiments, the cancer comprises urothelial cancer. In some embodiments, the urothelial cancer comprises bladder cancer. In some embodiments, the cancer comprises rectal cancer. In some embodiments, the cancer comprises thymus cancer. In some embodiments, the cancer comprises a sarcoma. e. Identification of the mutation or deletion of the gene (e.g., HSP90AB1 or ATM gene)
[0082] In some embodiments, the cancer has been determined (e.g., previously determined) to comprise the mutation or deletion (e.g., of the HSP90AB1 or an ATM gene). The presence of the mutation of the gene or deletion of the gene may be determined before administration ofthe composition. For example, the determination (e.g., previous identification) of the mutation or the deletion may take place months, weeks, days, hours, or even minutes ahead of the administering of the composition (e.g., the composition comprising a Hsp90 inhibitor). The determination of the presence of the mutation in the gene or deletion of the gene (e.g., the HSP90AB1 or ATM gene) may be conducted in any appropriate manner, including, but not limited to, identification of a gene mutation or gene deletion by any one or more tests discussed herein.
[0083] In some embodiments, the mutation or deletion of the HSP90AB1 or ATM gene is a cause or a result of the cancer.
[0084] In some embodiments, the cancer has been determined (e.g., previously determined) as comprising a reduced amount or function of ATM protein kinase or Hsp90p. The presence of the reduced amount of function of ATM protein kinase or Hsp90p may be determined before administration of the composition. For example, the identification of the reduced amount of function of ATM protein kinase or Hsp90p may take place months, weeks, days, hours, or even minutes ahead (i.e., previously identified) of the administering of the composition (e.g., the composition comprising a Hsp90 inhibitor). Determination of the presence of the reduced amount of ATM protein kinase or Hsp90p or function of ATM protein kinase or Hsp90p may be conducted in any appropriate manner, including, but not limited to, identification by of any one or more tests discussed herein.
[0085] In some embodiments, the reduced amount or function of ATM protein kinase or Hsp90p is a cause or result of the cancer. In some embodiments, the reduced amount or function of Hsp90 is not a result of pharmacological inhibition. For example, in such embodiments, the reduced amount or function of ATM protein kinase or Hsp90p is not caused by administration of a ATM inhibitor or an Hsp90 inhibitor.
[0086] The mutation (e.g., loss of function mutation or deletion in or of a HSP90AB1 or an ATM gene) may be any acceptable type of mutation, such as, for example, a substitution mutation, an insertion mutation, a deletion mutation, or a combination thereof. Determination of whether the mutation or deletion of the gene may be used to determine whether a patient comprises a reduced amount or function of ATM protein kinase or Hsp90p as compared to a wild-type amount or function of ATM protein kinase or Hsp90p. In some embodiments, the mutation is a substitution mutation. In some embodiments, the mutation is an insertion mutation. In some embodiments, the mutation is a deletion mutation.
[0087] Determining if a tumor has a genetic mutation may include identifying mutations in DNA extracted from a tumor sample and / or in circulating tumor or tumor cell DNA. In someembodiments, the cancer is determined to comprise the mutation before administration of the Hsp90 inhibitor (i.e., the cancer is previously determined as comprising the mutation).
[0088] Multiple tests may be employed to detect mutations or deletions. For example, tests may include sequencing of the tumor DNA using Sanger sequencing of PCR-amplified gene encoding regions or next-gen sequencing (NGS) of whole genome or captured / enriched gene encoding regions (e.g., through whole-exome sequencing, or sequencing of a targeted mutation panel that includes gene exons and introns).
[0089] Mutations may also be detected in RNA. Such RNA mutations may be detected using RNA- Seq or DNA approaches to sequence cDNA derived from RNA. Furthermore, mutations may be detected through targeted amplification of variants and sequenced by next-generation sequencing (NGS) or through array-based readout of genetic variants (e.g. using Illumina BeadArrays). Tumor DNA may be derived from biopsy samples or captured from indirect tumor sources, such as blood derived cell-free DNA.
[0090] Function and amount of Hsp90 may be determined through any acceptable method, including, for example, methods that measure the phosphorylation levels of known ATM or HSP90AB1 signaling components. Methods to quantify these modifications may include western blots, mass-spectrometry, protein binding arrays, or immunohistochemistry. Some examples of markers that may be used for measuring function and amounts of Hsp90 include, but are not limited to Hsp70, Hop, CDC37, Hsp40, or a combination thereof. f. Improving cancer treatment efficacy
[0091] Methods provided herein may be useful in treating a cancer, such as, for example, by increasing cancer cell inhibition or decreasing cancer progression. “Increases cancer cell inhibition” may mean decreasing cancer cell viability or inhibiting cancer cell growth or proliferation.
[0092] In some embodiments, the administering of a Hsp90 inhibitor increases cancer cell inhibition. In some embodiments, the administering of a Hsp90 inhibitor increases cancer cell inhibition as compared to a different treatment. In some embodiments, administering of a Hsp90 inhibitor increases cancer cell inhibition in a cancer comprising a loss of function mutation or a deletion of a HSP90AB1 or an ATM gene compared to a corresponding administration of said Hsp90 inhibitor to a second cancer that does not have a loss of function mutation or a deletion of a HSP90AB1 or an ATM gene. In some embodiments, administering of a Hsp90 inhibitor increases cancer cell inhibition in a cancer comprising a reduced amount or function of Hsp90 compared to a corresponding administration of said Hsp90 inhibitor to a second cancer that does not have a reduced amount or function of Hsp90.g. Administration
[0093] Administration of the composition comprising a Hsp90 inhibitor may be accomplished by any acceptable means, including, for example, by parenteral administration. Acceptable means of parenteral administration include, but are not limited to, subcutaneous administration, intramuscular administration, and intravenous administration. In some embodiments, the method comprises administering a Hsp90 inhibitor. In some embodiments, administering comprises administering the Hsp90 inhibitor parenterally. In some embodiments, the method comprises administering a pharmaceutical composition comprising a Hsp90 inhibitor (e.g., such as any of the pharmaceutical compositions provided herein).
[0094] In some embodiments, administering comprises administering the Hsp90 inhibitor enterally. Acceptable means of enteral administration include, but are not limited to, oral administration, gastric administration, and rectal administration.
[0095] In some embodiments, administering occurs once daily. In some embodiments, administering occurs twice daily. In some embodiments, administering occurs three times daily. h. Pharmaceutical Compositions
[0096] The Hsp90 inhibitor may be delivered in the form of a pharmaceutical composition. In some embodiments, the pharmaceutical composition comprises a Hsp90 inhibitor (e.g., luminespib). The pharmaceutical composition may be useful in the treatment of a cancer, such as, for example, a cancer determined as comprising a loss of function mutation or a deletion of a HSP90AB1 or an ATM gene or a cancer determined as comprising a reduced amount or function of ATM protein kinase or Hsp90p as compared to a wild-type amount or function of ATM protein kinase or Hsp90p.
[0097] The compositions described herein may comprise any appropriate Hsp90 inhibitor, such as, for example, any of the Hsp90 inhibitors described herein (e.g., luminespib). In some embodiments, the Hsp90 inhibitor is a stereoisomer, pharmaceutically acceptable salt, hydrate, or solvate of a Hsp90 inhibitor described herein. In some embodiments, the pharmaceutical composition comprises a Hsp90 inhibitor and a pharmaceutically acceptable carrier (e.g., one or more pharmaceutically acceptable carrier, two or more pharmaceutically acceptable carriers, three or more pharmaceutically acceptable carriers, etc.). The carrier(s) may be any acceptable or suitable described herein. In some embodiments, the pharmaceutical composition comprising a Hsp90 inhibitor is administered in a method of treating a patient (e.g., comprising a HSP90AB1 loss of function mutation or a deletion of HSP90AB1).
[0098] In certain embodiments, the Hsp90 inhibitor described herein is administered as a pure chemical (i.e., not with an excipient). In some embodiments, the Hsp90 inhibitor describedherein is combined with a pharmaceutically suitable or acceptable carrier (which may also be referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration and standard pharmaceutical practice as described.
[0099] In some embodiments, the pharmaceutical composition comprising a Hsp90 inhibitor is formulated for oral administration. Suitable oral dosage forms include, but are not limited to, tablets, pills, sachets, or capsules.
[0100] In some embodiments, the pharmaceutical composition comprising a Hsp90 inhibitor is formulated for administration by injection. In some instances, the injection formulation is an aqueous formulation. In some instances, the injection formulation is a non-aqueous formulation. In some instances, the injection formulation is an oil-based formulation, such as sesame oil, or the like.
[0101] The dose of the composition comprising a Hsp90 inhibitor may differ depending upon the subject or patient's condition. Such factors for consideration may include general health status, age, and other factors.
[0102] The pharmaceutical compositions described herein may be administered in any manner appropriate for the treatment or prevention of the disease (e.g., cancer). An appropriate dose and a suitable duration and frequency of administration may be determined by factors related to the condition of the patient, such as the type and severity of the patient's disease, the patient’s age, weight, body surface area, etc. Alternatively, an appropriate dose and a suitable duration and frequency of administration may be determined by factors related to the composition, such as the particular form of the active ingredient, and the method of administration. In cases, the appropriate dose is determined by factors related to both the condition of the patient and the composition. In general, an appropriate dose and treatment regimen may provide the composition(s) in an amount sufficient to provide therapeutic and / or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and / or overall survival). Optimal doses are generally determined using experimental models and / or clinical trials. The optimal dose may depend upon the body mass, weight, or blood volume of the patient.II. Kits for Treating CancerFurther provided herein, in some embodiments, are kits for treating a cancer, comprising: a test for determining a loss of function mutation or a deletion of a gene, and a heat shock protein 90 (“Hsp90”) inhibitor; wherein said gene is a HSP90AB1 gene, or an ataxiatel angiectasia mutated (“ATM”) gene. In some embodiments, said Hsp90 inhibitor comprises a compound selected from a small molecule drug or a biologic drug. In some embodiments, said biologic drug comprises a compound selected from an antibody, a peptide, a vaccine, or a combination thereof. In some embodiments, said Hsp90 inhibitor comprises a small molecule drug. In some embodiments, said small molecule Hsp90 inhibitor is selected from luminespib, ganetespib, onalespib, 17-AAG, SNX-5422, XL-888, BIIB-021, zelavespib, 17-DMAG, BUB- 028, DS 2248, retaspimycin, arimoclomol, CTXT-102, SGX-301, RTA 901, T-2143, TAS- 116, PU-AD, In some embodiments, HSP 990, icapamespib, KW 2478, LAM-003, locnartecan, MPC 3100, TQB 3474, WP-1303, geldanamycin, IPI-493, MPC-3100, Debio0932, VER-82576, or a combination thereof. In some embodiments, HSP 990, icapamespib, KW 2478, LAM-003, locnartecan, MPC 3100, TQB 3474, WP-1303, geldanamycin, IPI-493, MPC-3100, Debio0932, VER-82576, or any combination thereof. In some embodiments, said small molecule Hsp90 inhibitor is selected from luminespib, ganetespib, onalespib, 17-AAG, SNX-5422, XL-888, BIIB-021, zelavespib, 17-DMAG, BUB- 028, DS 2248, retaspimycin, arimoclomol, CTXT-102, SGX-301, RTA 901, T-2143, TAS- 116, PU-AD, or any combination thereof. In some embodiments, said cancer comprises lung cancer, colorectal cancer, urinary tract cancer, uterine cancer, stomach cancer, ovarian cancer, breast cancer, colon cancer, or a combination thereof.Definitions
[0103] As used in the specification and appended claims, unless specified to the contrary, the following terms have the meaning indicated below.
[0104] The singular forms (e.g., "a," "and," and "the") include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an agent" includes a plurality of such agents, and reference to "the cell" includes reference to one or more cells (or to a plurality of cells) and equivalents thereof known to those skilled in the art, and so forth. When ranges are used herein for physical properties, such as molecular weight, or chemical properties, such as chemical formulae, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included.
[0105] The term "about" when referring to a number or a numerical range means that the number or numerical range referred to is an approximation within experimental variability (or within statistical experimental error), and thus the number or numerical range, in some instances, the term “about” preceding a stated value includes the stated value and also includes ±20% of the stated value or range, and includes more specifically values of ±10%, ±5%, ±2%, and ±1% of the stated value or range.
[0106] The term “associated” or “associated with” in the context of a disease, substance or substance activity or function associated with a disease means that the disease is caused by (in whole or in part), a symptom of the disease is caused by (in whole or in part) the substance or substance activity or function, or a side-effect of the compound (e.g. toxicity) is caused by (in whole or in part) the substance or substance activity or function.
[0107] The term "comprising" (and related terms such as "comprise" or "comprises" or "having" or "including") is not intended to exclude that in other certain embodiments, for example, an embodiment of any composition of matter, composition, method, or process, or the like, described herein, "consist of' or "consist essentially of' the described features.
[0108] “Disease” or “condition” refer to a state of being or health status of a patient or subject capable of being treated with the compounds or methods provided herein. In some embodiments, the disease as used herein refers to cancer.
[0109] As defined herein, the terms “inhibition”, “inhibit”, “inhibiting” and the like, when made in reference to a protein-inhibitor interaction, means negatively affecting (e.g., decreasing) the activity or function of the protein (e.g., Hsp90) relative to the activity or function of the protein in the absence of the inhibitor. The protein may be Hsp90. Thus, inhibition includes, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of a protein. Inhibition, and such terms, may refer to reduction of a disease or symptoms of disease when referred to in such context.
[0110] The compounds disclosed herein, in some embodiments, contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that are defined, in terms of absolute stereochemistry, as (R)- or (5)-. Unless stated otherwise, it is intended that all stereoisomeric forms of the compounds disclosed herein are contemplated by this disclosure. When the compounds described herein contain alkene double bonds, and unless specified otherwise, it is intended that this disclosure includes both E and Z geometric isomers (e.g., cis or trans.) Likewise, all possible isomers, as well as their racemic and optically pure forms, and all tautomeric forms are also intended to be included. The term “geometric isomer” refers to E or Z geometric isomers (e.g., cis or trans) of an alkene double bond. The term “positional isomer” refers to structural isomers around a central ring, such as ortho-, meta-, and para- isomers around a benzene ring.
[0111] As used herein, “delaying development of a disease” means to defer, hinder, slow, retard, stabilize, and / or postpone development of the disease (such as cancer). This delay can be of varying lengths of time, depending on the history of the disease and / or individual being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect,encompass prevention, in that the individual does not develop the disease. For example, a late stage cancer, such as development of metastasis, may be delayed.
[0112] The terms “selective” or “selectivity” “specific”, “specifically”, “specificity”, or the like of a compound refers to the compound’s ability to cause a particular action or the compound’s ability to discriminate between molecular targets, such as inhibition, to a particular molecular target (e.g., Hsp90).
[0113] As used herein, compounds providing inhibitory properties (e.g., a Hsp90 inhibitor), include small-molecule compounds and biological products (e.g., such as those derived from living material (e.g., antibodies, proteins, peptide fragments, etc), unless context clearly dictates otherwise.
[0114] A "tautomer" refers to a molecule wherein a proton shift from one atom of a molecule to another atom of the same molecule is possible. The compounds presented herein, in certain embodiments, exist as tautomers. In circumstances where tautomerization is possible, a chemical equilibrium of the tautomers will exist. The exact ratio of the tautomers depends on several factors, including physical state, temperature, solvent, and pH. Some examples of tautomeric equilibrium include:
[0115] "Pharmaceutically acceptable salt" includes both acid and base addition salts. A pharmaceutically acceptable salt of any one of the Hsp90 inhibitors described herein is intended to encompass any and all pharmaceutically suitable salt forms. Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
[0116] "Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically orotherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, and the like. Also included are salts that are formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and. aromatic sulfonic acids, etc. and include, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Exemplary salts thus include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinate suberates, sebacates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, and the like. Also contemplated are salts of amino acids, such as arginates, gluconates, and galacturonates (see, for example, Berge S.M. et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 66: 1-19 (1997)). Acid addition salts of basic compounds are, in some embodiments, prepared by contacting the free base forms with a sufficient amount of the desired acid to produce the salt according to methods and techniques with which a skilled artisan is familiar.
[0117] "Pharmaceutically acceptable base addition salt" refers to those salts that retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Pharmaceutically acceptable base addition salts are, in some embodiments, formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, for example, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, A,A-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, A-methylglucamine, glucosamine,methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. See Berge et al., supra.
[0118] "Pharmaceutically acceptable solvate" refers to a composition of matter that is the solvent addition form. In some embodiments, solvates contain either stoichiometric or non- stoichiometric amounts of a solvent, and are formed during the process of making with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of compounds described herein are conveniently prepared or formed during the processes described herein. The compounds provided herein exist in either unsolvated or solvated forms.
[0119] The term “subject”, “individual” or “patient” encompasses mammals. Examples of mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like. In one aspect, the mammal is a human.
[0120] As used herein, “mutations” may refer to change(s) in a polynucleotide sequence that result in changes to protein function. A change to protein function may occur through a change to the protein encoded by the polynucleotide sequence. The change in function of the protein may be altered through an amino acid sequence of the protein or by a change in the amount (e.g., in an expression level) of the protein, or both. Mutations can be nucleotide substitutions, such as single nucleotide substitutions, insertions, or deletions, and may end up altering the splicing of messenger RNA (mRNA), the levels of mRNA, and / or the amino acid sequence of the protein encoded by said mRNA.
[0121] As used herein, “treatment” or “treating,” or “palliating” or “ameliorating” are used interchangeably. These terms refer to an approach for obtaining beneficial or desired results, including, but not limited to, a therapeutic benefit and / or a prophylactic benefit. The term “therapeutic benefit”, or the like, may include eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit may be achieved with the eradication or amelioration of one or more of the symptoms associated with the underlying disorder such that an improvement may be observed in the patient, notwithstanding that the patient may still afflicted with the underlying disorder. For achieving a prophylactic benefit, the compositions may be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease has not been made.EXAMPLES
[0122] While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now' occur to those skilled in the art without departing from the invention. It. should be understood that, various alternatives to the embodiments described herein may be employed in practicing the invention. It is intended that, the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.Example 1 — Identification of Mutations in HSP90AB1 gene
[0123] Experiments are run in order to identify potential loss of function mutations and deletions in HSP90AB1 . Genomic DNA is extracted from FFPE-preserved tumor biopsy tissue. Targeted capture is used to enrich for the exome, including all coding exons of all HSP90AB1 isoforms. NGS libraries are constructed and indexed using Illumina TruSeq exome kits (cat number 20020614) and then sequenced on an Illumina HiSeq platform. Somatic mutations are then called (e.g. per methods described in PMID 24192750 or PMID 33106175). Genome variants (SNVs and indels) are identified using GATK (PMID 20644199), and somatic mutations are called using Mutect2 (PMID 23396013) and Varscan (PMID 19542151). The mutations are filtered to functional / deleterious mutations on the basis of causing amino acid substitutions or protein coding changes with a predicted functional effect inferred by MutationTaster (PMID 20676075), a “deleterious” flag inferred by SIFT (PMID 12824425), and / or a “probably damaging” flag inferred by Polyphen-2 (PMID 23315928). Loss of function (LOF) mutations are filtered from likely gain of function (GOF) variants based on the absence of hotspot variants in LOF mutations. For example, LOF mutations may be identified as those that do not result, for example, in substitutions / deletions / alterations among the commonly altered HSP90AB1 amino acids. Commonly altered HSP90AB1 amino acids may include 1, 38, 39, 81, 88, 90, 93, 104, 106, 107, 108, 111, 115, 118, 344, 345, 350, 357, 364, 365, 378, 420, 453, 471, 539, 542, 545, 546, 604, 726, 901, 939, 970, 1004, 1007, 1021, 1025, 1043, 1044, 1047, 1049, 1052, 1065, or a combination thereof. For example, one possible hotspot mutation for amino acid 545 is the mutation E545K, which is a change of glutamic acid at position 545 to lysine.
[0124] Deep deletions (e.g., which may include a complete (zero copy) loss of one or more regions of HSP90AB1 that overlap a portion of a coding exon or an entire coding exon) may also constitute HSP90AB1 LOF events. Deep deletions and a complete loss of the HSP90AB1gene are called from exome data using Control-FREEC (PMID 22155870). Western analysis and immunohistochemistry on FFPE preserved tumor biopsy is used to confirm a reduction or loss of HSP90AB1 gene expression at the protein level.Example 2- Identification of Mutations in ATM gene
[0125] Experiments are run in order to identify potential loss of function mutations and deletions in ATM. Genomic DNA is extracted from FFPE-preserved tumor biopsy tissue. Targeted capture is used to enrich for the exome, including all coding exons of all ATM isoforms. NGS libraries are constructed and indexed using Illumina TruSeq exome kits (cat number 20020614) and then sequenced on an Illumina HiSeq platform. Somatic mutations are then called (e.g. per methods described in PMID 24192750 or PMID 33106175). Genome variants (SNVs and indels) are identified using GATK (PMID 20644199), and somatic mutations are called using Mutect2 (PMID 23396013) and Varscan (PMID 19542151). The mutations are filtered to functional / deleterious mutations on the basis of causing amino acid substitutions or protein coding changes with a predicted functional effect inferred by MutationTaster (PMID 20676075), a “deleterious” flag inferred by SIFT (PMID 12824425), and / or a “probably damaging” flag inferred by Polyphen-2 (PMID 23315928). Loss of function (LOF) mutations are filtered from likely gain of function (GOF) variants based on the absence of hotspot variants in LOF mutations. For example, LOF mutations may be identified as those that do not result, for example, in substitutions / deletions / alterations among the commonly altered ATM amino acids.
[0126] Deep deletions (e.g., which may include a complete (zero copy) loss of one or more regions of ATM that overlap a portion of a coding exon or an entire coding exon) may also constitute ATM LOF events. Deep deletions and a complete loss of the ATM gene are called from exome data using Control-FREEC (PMID 22155870). Western analysis and immunohistochemistry on FFPE preserved tumor biopsy are used to confirm a reduction or loss of ATM gene expression at the protein level.Example 3 - Analysis of HSP90AB1 Loss of Function or Deletion in Patients with Tnmors Harboring HSP90AB1 Mutations
[0127] Precision medicine may provide some of the newest approaches to cancer treatment. Targeted therapeutics may be designed to exploit disease biology and to define which patients should receive a specific therapy. One concept underlying this approach is that the molecular features of a patient’s tumor may influence clinical response to a medication, and thus, may be used toguide therapy (e.g., medication selection). As such, precision medicine may lead to increased efficacy (e.g., increased tumor cell growth inhibition or death) and reduced toxicity.
[0128] Tumor genetics may be central to this approach. For example, cancer may be caused by driver mutations, which confer a selective advantage and may allow cancer cells to proliferate. Driver mutations may be used to define patients and may be highly predictive for drug activity; that is, the presence of a specific driver mutation may be an indicator of the effectiveness of a given therapy. Approximately one third of cancers may be caused by driver mutations that induce a gain of function (GOF) in oncogenes and result in a protein product that may be therapeutically targeted. The remaining two thirds of cancers are caused by a loss of function (LOF) mutation in a tumor suppressor gene (TSG). In healthy cells, TSGs may act to control cell growth and division; loss of function mutations in these genes may result in uncontrolled growth and cancer. Such cancers are typically more difficult to target than cancers resulting from GOF mutations, because in cancers resulting from a LOF mutation it is the absence of a functional protein that results in oncogenesis. Thus, a target is more difficult to ascertain. As evidence of this disparity in treatability, drugs exist against approximately 2 / 3 of oncogenes, but drugs exist for only ~2% of tumor suppressor genes (e.g., the PARPi targeting homologous recombination defects, e.g. BRCA1 / 2, ATM, ATR, mutations). One potential approach to targeting LOF cancers is to leverage vulnerabilities that are unique to tumor cells by identifying synthetic lethal (SL) interactions. In a synthetic lethality relationship between two genes a loss of function in either, but not both, is tolerated. Since only tumor cells contain the driver mutation, drugs that specifically target the mutation will only impact these tumor cells, and off-target effects, such as toxicities, are expected to be minimal. This approach may be applied to identify both genetic dependencies and small molecule sensitivities of cancer cell lines. As evidence of the importance of this approach, massive and ongoing efforts by large consortia are underway to comprehensively map synthetic lethal networks in hundreds of cancer cell lines with the goal of identifying drug targets and the patients who are expected to respond best to them.
[0129] While these efforts have provided valuable insights and identified potential drug candidates, significant challenges remain. For example, many patients do not benefit from targeted therapies because large-scale screens produce new target predictions and feed drug development pipelines at the entry point such that treatment is years away, and the drug(s) identified in screens (e.g., small molecule screens) may not recapitulate genetic perturbation profiles and SL relationships identified in cell lines may not translate to tumors in patients.
[0130] Using data from The Cancer Genome Atlas (“TCGA”; www.cancer.gov / tcga and PMID 28528867) the effect of HSP90AB1 LOF mutations on Hsp90 pathway activity was tested.First, the prevalence of HSP90AB1 LOF mutations / deletions in multiple cancers was evaluated. From data gathered from TCGA, subjects were organized into three categories for each of the cancer types captured by TCGA: 1) those comprising a HSP90AB1 LOF mutation (e.g., such as using the mutation calling criteria described in Example 1), 2) those comprising a wild-type (wt) HSP90AB1, or 3) those comprising a HSP90AB1 GOF mutation (e.g., comprising a hotspot mutation or more than 2 copies of HSP90AB1). The proportion of subjects with a HSP90AB1 LOF mutation / deletion was then evaluated for each of the respective cancers.Example 4 - Analysis of ATM Loss of Faction or Deletion in Patients with Tumors Harboring ATM Mutations or ATM Mutations
[0131] Precision medicine may provide some of the newest approaches to cancer treatment. Targeted therapeutics may be designed to exploit disease biology and to define which patients should receive a specific therapy. One concept underlying this approach is that the molecular features of a patient’s tumor may influence clinical response to a medication, and thus, may be used to guide therapy (e.g., medication selection). As such, precision medicine may lead to increased efficacy (e.g., increased tumor cell growth inhibition or death) and reduced toxicity.
[0132] Tumor genetics may be central to this approach. For example, cancer may be caused by driver mutations, which confer a selective advantage and may allow cancer cells to proliferate. Driver mutations may be used to define patients and may be highly predictive for drug activity; that is, the presence of a specific driver mutation may be an indicator of the effectiveness of a given therapy. Approximately one third of cancers may be caused by driver mutations that induce a gain of function (GOF) in oncogenes and result in a protein product that may be therapeutically targeted. The remaining two thirds of cancers are caused by a loss of function (LOF) mutation in a tumor suppressor gene (TSG). In healthy cells, TSGs may act to control cell growth and division; loss of function mutations in these genes may result in uncontrolled growth and cancer. Such cancers are typically more difficult to target than cancers resulting from GOF mutations, because in cancers resulting from a LOF mutation it is the absence of a functional protein that results in oncogenesis. Thus, a target is more difficult to ascertain. As evidence of this disparity in treatability, drugs exist against approximately 2 / 3 of oncogenes, but drugs exist for only ~2% of tumor suppressor genes (e.g., the PARPi targeting homologous recombination defects, e.g. BRCA1 / 2, ATM, ATR, mutations). One potential approach to targeting LOF cancers is to leverage vulnerabilities that are unique to tumor cells by identifying synthetic lethal (SL) interactions. In a synthetic lethality relationship between two genes a loss of function in either, but not both, is tolerated. Sinceonly tumor cells contain the driver mutation, drugs that specifically target the mutation will only impact these tumor cells, and off-target effects, such as toxicities, are expected to be minimal. This approach may be applied to identify both genetic dependencies and small molecule sensitivities of cancer cell lines. As evidence of the importance of this approach, massive and ongoing efforts by large consortia are underway to comprehensively map synthetic lethal networks in hundreds of cancer cell lines with the goal of identifying drug targets and the patients who are expected to respond best to them.
[0133] While these efforts have provided valuable insights and identified potential drug candidates, significant challenges remain. For example, many patients do not benefit from targeted therapies because large-scale screens produce new target predictions and feed drug development pipelines at the entry point such that treatment is years away, and the drug(s) identified in screens (e.g., small molecule screens) may not recapitulate genetic perturbation profiles and SL relationships identified in cell lines may not translate to tumors in patients.
[0134] Using data from TCGA the effect of ATM LOF mutations on Hsp90 pathway activity was tested. First, the prevalence of ATM LOF mutations / deletions in multiple cancers was evaluated. From data gathered from TCGA, subjects were organized into three categories for each of the cancer types captured by TCGA: 1) those comprising a ATM LOF mutation (e.g., such as using the mutation calling criteria described in Example 2), 2) those comprising a wild-type (wt) ATM, or 3) those comprising a ATM GOF mutation (e.g., comprising a hotspot mutation or more than 2 copies of ATM). The proportion of subjects with a ATM LOF mutation / deletion was then evaluated for each of the respective cancersExample 5 - A Study of Onalespib screen in KP4 cells with gene mutations
[0135] 182 driver gene mutations were tested for synergy with onalespib. Each point is a mutation that we introduced into cells and tested for viability in presence of onalespib compared to DMSO (Vehicle Control). The results of this analysis are shown in a Volcano Plot in Fig. 1. Points on the left-hand side of the plot indicate cells growing slower in the presence of onalespib . Points on the right-hand side of the plot indicate mutations that accelerate growth in the presence of onalespib relative to vehicle. The Y-axis is the statistical significance of the effect.Example 6 - A Study of Hsp90 Inhibitors for the Treatment of Tumors Harboring HSP90AB1 Mutations
[0136] To determine the effects of Hsp90 inhibitors in tumor cells harboring HSP90AB1 mutations, cell lines with engineered HSP90AB1 were created and administered multiple Hsp90inhibitors. In particular, an engineered line comprising a HSP90AB1 loss of function (LOF) mutant was compared to its parental line (HSP90AB1 wild type). Various Hsp90 inhibitors were administered to each cell line.
[0137] To create cells with a loss of function HSP90AB1 mutation (HSP90AB1 -LOF mutant), the HSP90AB1 gene was knocked out in KP4 cells using CRISPR genome editing (kits sold by Synthego). The parental line of KP4 cells comprising HSP90AB1 wild type was used as a comparator. A cell viability assay was performed by treating the cell lines with various concentrations of different Hsp90 inhibitors.
[0138] As shown in FIGs. 2A, 3, 4, 5, 6A, and 8, cells having an HSP90AB1 LOF mutation exhibited increased sensitivity to Hsp90 inhibitors (zelavespib, SNX-5422, onalespib, XL- 888, luminespib, and 17-AAG, respectively), compared to parental cell line. The results of this experiment demonstrate synthetic lethality between the tested Hsp90 inhibitors and an HSP90AB1 loss of function mutation.Example 7 - A Study of Hsp90 Inhibitors for the Treatment of Tumors Harboring ATM Mutations
[0139] To determine the effects of Hsp90 inhibitors in tumor cells harboring ATM mutations, cell lines with engineered ATM were created and administered multiple Hsp90 inhibitors. In particular, an engineered line comprising an ATM loss of function (LOF) mutant was compared to its parental line (ATM wild type). Various Hsp90 inhibitors were administered to each cell line.
[0140] To create cells with a loss of function ATM mutation (ATM -LOF mutant), the ATM gene was knocked out in SW780 cells using CRISPR genome editing (kits sold by Synthego). The parental line of KP4 cells comprising ATM wild type was used as a comparator. A cell viability assay was performed by treating the cell lines with various concentrations of different Hsp90 inhibitors. As shown in FIGs. 2B, 6B, and 7, cells having an ATM LOF mutation exhibited increased sensitivity to Hsp90 inhibitors (e.g., zelavespib, luminespib, and ganetespib) compared to parental cell line. The results of this experiment demonstrate synthetic lethality between the tested Hsp90 inhibitors and an ATM loss of function mutation.Example 8. Cellular Assay
[0141] To study the effect of additional Hsp90 inhibitors on cells with a HSP90AB1 LOF mutation, cells with and without HSP90AB1 LOF mutations are administered a Hsp90 inhibitor.
[0142] Isogenic pairs of KP4 cell lines differing only in their HSP90AB1 mutation status (with and without HSP90AB1 loss of function) are generated. Synthego CRISPR Gene Knockout v2kits are used to knock out HSP90AB1 in KP4 cells (where HSP90AB1 is wild type and present in 2 copies; PMID 23550210). The knockout of HSP90AB1 is confirmed by Sanger sequencing and Synthego analysis software. Cells in 96-well plates at 2000 cells / well are seeded in triplicate and treated with varying concentrations of Hsp90 inhibitors spanning a 3x dilution gradient from 50 uM to sub-nanomolar concentrations. Five days after treatment initiation, cell viability is determined by cell titer gio.
[0143] The curves will reveal a dose-dependent response to Hsp90 inhibitors, with higher concentrations leading to greater reductions in cell viability, and overall higher sensitivity in cells with HSP90AB1 knocked out (e.g.,. a lower concentration of drug would yield the same reduction of viability in HSP90AB1 -LOF vs HSP90AB1 wt).Example 9. Cellular Assay
[0144] To study the effect of additional Hsp90 inhibitors on cells with a ATM LOF mutation, cells with and without ATM LOF mutations are administered a Hsp90 inhibitor.
[0145] Isogenic pairs of KP4 cell lines differing only in their ATM mutation status (with and without ATM loss of function) are generated. Synthego CRISPR Gene Knockout v2 kits are used to knock out ATM in KP4 cells (where ATM is wild type and present in 2 copies; PMID 23550210). The knockout of ATM is confirmed by Sanger sequencing and Synthego analysis software. Cells in 96-well plates at 2000 cells / well are seeded in triplicate and treated with varying concentrations of Hsp90 inhibitors spanning a 3x dilution gradient from 50 uM to sub-nanomolar concentrations. Five days after treatment initiation, cell viability is determined by cell titer gio.
[0146] The curves will reveal a dose-dependent response to Hsp90 inhibitors, with higher concentrations leading to greater reductions in cell viability, and overall higher sensitivity in cells with ATM knocked out (e.g.,. a lower concentration of drug would yield the same reduction of viability in ATM -LOF vs ATM wt).Example 10. Xenograft Study Using Cell Derived Xenograft Models
[0147] Heightened sensitivity to a Hsp90 inhibitor (e.g., zelavespib) caused by loss of function of HSP90AB1 will be analyzed in vivo using cell derived xenograft (CDX) models with isogenic paired KP4 cells (with / without HSP90AB1 knocked out). Study design includes 30 mice, 15 for each treatment (mice with HSP90AB1 LOF and mice with HSP90AB1 wild type). 5 replicates across 3 groups will be utilized, with the mice receiving vehicle (no treatment), 3 mg / kg of a Hsp90 inhibitor, or 10 mg / kg of a Hsp90 inhibitors. Cells are implanted intoimmunocompromised mice and allowed the tumors to grow to a palpable size. Over 28 days of treatment, tumors are sized using calipers.
[0148] A larger reduction in tumor growth will be observed in both drug treated (3 mg / kg and 10 mg / kg) HSP90AB1 LOF groups, compared to vehicle HSP90AB1 LOF control and HSP90AB1 wild type treatment groups. Furthermore, there will be no significant weight loss at any dose of treatment.Example 11. Xenograft Study Using Cell Derived Xenograft Models
[0149] Heightened sensitivity to a Hsp90 inhibitor (e.g., zelavespib) caused by loss of function of ATM will be analyzed in vivo using cell derived xenograft (CDX) models with isogenic paired KP4 cells (with / without knocked ATM). Study design includes 30 mice, 15 for each treatment (mice with ATM LOF and mice with ATM wild type ). 5 replicates across 3 groups will be utilized, with the mice receiving vehicle (no treatment), 3 mg / kg of a Hsp90 inhibitor, or 10 mg / kg of a Hsp90 inhibitors. Cells are implanted into immunocompromised mice and allowed the tumors to grow to a palpable size. Over 28 days of treatment, tumors are sized using calipers.
[0150] A larger reduction in tumor growth will be observed in both drug treated (3 mg / kg and 10 mg / kg) ATM LOF groups, compared to vehicle ATM LOF control and ATM wild type treatment groups. Furthermore, there will be no significant weight loss at any dose of treatment.Example 12. Xenograft Study Using Patient Derived Xenograft Models
[0151] To investigate the potential for using Hsp90 inhibitor (e.g., zelavespib) to treat tumors with HSP90AB1 -LOF, patient derived xenograft (PDX) models with predicted LOF mutations in HSP90AB1 are identified from the NCI Patient Derived Model Repository (PDMR) and at Jackson Labs (J AX). Analysis of whole exome sequencing data to identify LOF HSP90AB1 mutations are done using methods, such as those described in Example 1. GATK and Samtools are used to call likely somatic single nucleotide variants (SNVs) and indels, which are then filtered on high likelihood of inducing a protein functional change, and further distinguished from gain of function (GOF) mutations on not being in sequence or structural hotspot regions. Loss of function (LOF) status is further reinforced on the basis of reduced expression of HSP90AB1 relative to other PDX models of the same cancer type. A variant allele frequency of at least 0.4 is required (at least 40% of the sequence reads that overlap the mutation contained the mutation in their sequence). Three exemplary models that met thecriteria included: 997537-175-T colon model (PDMR), 475296-252-R rectal model (PDMR), and TM01117 breast model (J AX).
[0152] PDX samples harboring a HSP90AB1 LOF mutation selected using the criteria described above, are cut to a uniform size and implanted subcutaneously into bilateral flanks of 5-week- old NSG mice sourced from JAX. For each study (i.e. each model), a 3x8 (3 treatments, 8 replicates) experimental design is employed. Tumors are measured every other day until tumor volume reached approximately 150 mm3. Hsp90 inhibitor (e.g., zelavespib) is administered at three doses (10 mg / kg and 3 mg / kg and vehicle control) once daily by oral gavage. Tumor sizes are recorded daily, and body weights are measured every 7 days to monitor for drug toxicity. Tumor volume is calculated using the following formula: tumor volume (mm3) = 1 / 2 (W)2 x (L). Mice are sacrificed once tumors reached 1000 mm3. Differential outcomes are determined through a log rank Kaplan-Meier survival analysis.
[0153] Mice treated with either dose of Hsp90 inhibitor (e.g., zelavespib) will achieve significantly improved survival outcomes with significantly reduced tumor growth.Example 13. Xenograft Study Using Patient Derived Xenograft Models
[0154] To investigate the potential for using Hsp90 inhibitor (e.g., zelavespib) to treat tumors with ATM -LOF, patient derived xenograft (PDX) models with predicted LOF mutations in ATM are identified from the NCI Patient Derived Model Repository (PDMR) and at Jackson Labs (JAX). Analysis of whole exome sequencing data to identify LOF ATM mutations are done using methods, such as those described in Example 1. GATK and Samtools are used to call likely somatic single nucleotide variants (SNVs) and indels, which are then filtered on high likelihood of inducing a protein functional change, and further distinguished from gain of function (GOF) mutations on not being in sequence or structural hotspot regions. Loss of function (LOF) status is further reinforced on the basis of reduced expression of ATM relative to other PDX models of the same cancer type. A variant allele frequency of at least 0.4 is required (at least 40% of the sequence reads that overlap the mutation contained the mutation in their sequence). Three exemplary models that met the criteria included: 997537-175-T colon model (PDMR), 475296-252-R rectal model (PDMR), and TM01117 breast model (JAX).
[0155] PDX samples harboring a ATM LOF mutation selected using the criteria described above, are cut to a uniform size and implanted subcutaneously into bilateral flanks of 5-week-old NSG mice sourced from JAX. For each study (i.e. each model), a 3x8 (3 treatments, 8 replicates) experimental design is employed. Tumors are measured every other day until tumor volume reached approximately 150 mm3. Hsp90 inhibitor (e.g., zelavespib) is administered at threedoses (10 mg / kg and 3 mg / kg and vehicle control) once daily by oral gavage. Tumor sizes are recorded daily, and body weights are measured every 7 days to monitor for drug toxicity. Tumor volume is calculated using the following formula: tumor volume (mm3) = 1 / 2 (W)2 x (L). Mice are sacrificed once tumors reached 1000 mm3. Differential outcomes are determined through a log rank Kaplan-Meier survival analysis.
[0156] Mice treated with either dose of Hsp90 inhibitor (e.g., zelavespib) will achieve significantly improved survival outcomes with significantly reduced tumor growth.Example 14. Patient Selection
[0157] Tumor derived FFPE biopsy samples are used to identify subjects with a LOF of HSP90AB1. Next-generation sequencing (NGS) of a targeted gene panel that includes all exons of HSP90AB1 are used to generate sequencing data. Mutations are called using methods such as those as described in Example 1. Subjects with an adjusted variant allele frequency (adjVAF) that accounts for normal tissue contribution in the biopsy are selected for treatment with a Hsp90 inhibitor if their adjVAF exceeded 0.3, which indicates that the LOF mutation occurred relatively early in the development of the tumor.Example 15. Patient Selection
[0158] Tumor derived FFPE biopsy samples are used to identify subjects with a LOF of ATM. Nextgeneration sequencing (NGS) of a targeted gene panel that includes all exons of ATM are used to generate sequencing data. Mutations are called using methods such as those as described in Example 1. Subjects with an adjusted variant allele frequency (adjVAF) that accounts for normal tissue contribution in the biopsy are selected for treatment with a Hsp90 inhibitor if their adjVAF exceeded 0.3, which indicates that the LOF mutation occurred relatively early in the development of the tumor.
[0159] The examples and embodiments described herein are for illustrative purposes only and various modifications or changes suggested to persons skilled in the art are to be included within the spirit and purview of this application and scope of the appended claims.
Claims
CLAIMSWe claim:
1. A method of treating a cancer in a patient in need thereof, said method comprising: administering a composition comprising a heat shock protein 90 (“Hsp90”) inhibitor, wherein said cancer has been previously determined as comprising a loss of function mutation or a deletion of a gene, wherein said gene is a HSP90AB1 gene or an ataxia telangiectasia mutated (“ATM”) gene.
2. The method of claim 1, wherein said loss of function mutation or deletion of said gene reduces an amount or activity of a gene product as compared to a wild-type amount or activity of said the gene product.
3. The method of claim 2, wherein said gene product comprises Hsp90p or ATM protein kinase.
4. A method of treating a cancer in a patient in need thereof, said method comprising: administering a composition comprising a heat shock protein 90 (“Hsp90”) inhibitor, wherein said patient has been previously determined as comprising a reduced amount or function of Hsp90p or ATM protein kinase as compared to a wild-type amount or function of Hsp90p or ATM protein kinase, respectively.
5. The method of claim 4, wherein a loss of function mutation or a deletion of a gene reduces the amount or function of Hsp90p or ATM protein kinase.
6. The method of claim 4, wherein a loss of function mutation or a deletion of a gene reduces the amount or function of Hsp90p.
7. The method of claim 4, wherein a loss of function mutation or a deletion of a gene reduces the amount or function of ATM protein kinase.
8. The method of claim 4, wherein epigenetic silencing or translation silencing reduces the amount or function of Hsp90p or ATM protein kinase.
9. The method of claim 4, wherein epigenetic silencing or translation silencing reduces the amount or function of Hsp90p.
10. The method of claim 4, wherein epigenetic silencing or translation silencing reduces the amount or function of ATM protein kinase.
11. The method of any one of claims 4-8, wherein said patient has been previously determined as comprising a reduced amount or function of ATM protein kinase as compared to a wild-type amount or function of ATM protein kinase.
12. The method of any one of claims 4-8, wherein said patient has been previously determined as comprising a reduced amount or function of Hsp90p as compared to a wild-type amount or function of Hsp90p.
13. The method of any one of claims 1-12, wherein said Hsp90 inhibitor comprises a compound selected from a small molecule drug or a biologic drug.
14. The method of claim 13, wherein said biologic drug comprises a compound selected from an antibody, a peptide, a vaccine, an or a combination thereof.
15. The method of any one of claims 1-13, wherein said Hsp90 inhibitor comprises a small molecule drug.
16. The method of claim 1, wherein said small molecule drug comprises luminespib, ganetespib, onalespib, 17-AAG, SNX-5422, XL-888, BIIB-021, zelavespib, 17- DMAG, BUB-028, DS 2248, retaspimycin, arimoclomol, CTXT-102, SGX-301, RTA 901, T-2143, TAS-116, PU-AD, or a combination thereof.
17. The method of any one of claims 1-16, wherein said gene is the HSP90AB1 gene.
18. The method of claim 17, wherein said cancer comprises lung cancer, colorectal cancer, urinary tract cancer, uterine cancer, stomach cancer, ovarian cancer, pancreatic cancer, breast cancer, or a combination thereof.
19. The method of claim 18, wherein said cancer comprises uterine cancer.
20. The method of claim 19, wherein the uterine cancer comprises endometrial cancer.
21. The method of claim 20, wherein said endometrial cancer is uterine corpus endometrial carcinoma.
22. The method of claim 19, wherein the uterine cancer comprises uterine sarcoma.
23. The method of claim 22, wherein the uterine sarcoma comprises uterine carcinosarcoma.
24. The method of claim 18, wherein said cancer comprises lung cancer.
25. The method of claim 24, wherein said lung cancer comprises non-small cell lung cancer.
26. The method of claim 18, wherein said cancer comprises colorectal cancer.
27. The method of claim 18, wherein said cancer comprises urinary tract cancer.
28. The method of claim 27, wherein said urinary tract cancer comprises bladder cancer.
29. The method of claim 28, wherein said bladder cancer comprises a carcinoma.
30. The method of claim 29, wherein said carcinoma comprises urothelial carcinoma.
31. The method of claim 27, wherein said urinary tract cancer comprises kidney cancer.
32. The method of claim 18, wherein said cancer comprises stomach cancer.
33. The method of claim 18, wherein said cancer comprises ovarian cancer.
34. The method of any one of claims 1-16, wherein said gene is the ATM gene.
35. The method of claim 34, wherein said cancer comprises lung cancer, colorectal cancer, urinary tract cancer, uterine cancer, breast cancer, stomach cancer, colon cancer, pancreatic cancer, or a combination thereof.
36. The method of claim 35, wherein said cancer comprises uterine cancer.
37. The method of claim 36, wherein the uterine cancer comprises endometrial cancer.
38. The method of claim 37, wherein said endometrial cancer is uterine corpus endometrial carcinoma.
39. The method of claim 36, wherein the uterine cancer comprises uterine sarcoma.
40. The method of claim 39, wherein the uterine sarcoma comprises uterine carcinosarcoma.
41. The method of claim 35, wherein said cancer comprises lung cancer.
42. The method of claim 41, wherein said lung cancer comprises non-small cell lung cancer.
43. The method of claim 35, wherein said cancer comprises colorectal cancer.
44. The method of claim 35, wherein said cancer comprises urinary tract cancer.
45. The method of claim 35, wherein said urinary tract cancer comprises bladder cancer.
46. The method of claim 45, wherein said bladder cancer comprises a carcinoma.
47. The method of claim 46, wherein said carcinoma comprises urothelial carcinoma.
48. The method of claim 35, wherein said cancer comprises stomach cancer.
49. The method of claim 35, wherein said cancer comprises breast cancer.
50. The method of claim 35, wherein said cancer comprises colon cancer.
51. The method of any one of the previous claims, wherein the Hsp90 inhibitor comprises luminespib.
52. The method of any one of the previous claims, wherein the Hsp90 inhibitor comprises ganetespib.
53. The method of any one of the previous claims, wherein the Hsp90 inhibitor comprises a second generation Hsp90 inhibitor.
54. The method of any one of the previous claims, wherein the second generation Hsp90 inhibitor comprises onalespib.
55. The method of any one of the previous claims, wherein the Hsp90 inhibitor comprises XL-888.
56. The method of any one of the previous claims, wherein the Hsp90 inhibitor comprises 17-AAG.
57. The method of any one of the previous claims, wherein the Hsp90 inhibitor comprises SNX-5422.
58. The method of any one of the previous claims, wherein the Hsp90 inhibitor comprises BUB-021.
59. The method of any one of the previous claims, wherein the Hsp90 inhibitor comprises zelavespib.
60. The method of any one of the previous claims, wherein the Hsp90 inhibitor comprises 17-DMAG.
61. The method of any one of the previous claims, wherein the Hsp90 inhibitor comprises BUB-028.
62. The method of any one of the previous claims, wherein the Hsp90 inhibitor comprises DS 2248.
63. The method of any one of the previous claims, wherein the Hsp90 inhibitor comprises retaspimycin.
64. The method of any one of the previous claims, wherein the Hsp90 inhibitor comprises arimoclomol.
65. The method of any one of the previous claims, wherein the Hsp90 inhibitor comprises CTXT-102.
66. The method of any one of the previous claims, wherein the Hsp90 inhibitor comprises SGX-301.
67. The method of any one of the previous claims, wherein the Hsp90 inhibitor comprises RTA 901.
68. The method of any one of the previous claims, wherein the Hsp90 inhibitor comprises T-2143.
69. The method of any one of the previous claims, wherein the Hsp90 inhibitor comprises TAS-116.
70. The method of any one of the previous claims, wherein the Hsp90 inhibitor comprises PU-AD.
71. The method of any one of the previous claims wherein said loss of function or said deletion of said gene is a result of epigenetic silencing or translation silencing.
72. A kit for treating a cancer, comprising: a. a test for determining a loss of function mutation or a deletion of a gene, and b. a heat shock protein 90 (“Hsp90”) inhibitor; wherein said gene is a HSP90AB1 gene, HSP90AA1 gene, or an ataxia telangiectasia mutated (“ATM”) gene.
73. The kit of claim 72, wherein said Hsp90 inhibitor comprises a compound selected from a small molecule drug or a biologic drug.
74. The kit of claim 73, wherein said biologic drug comprises a compound selected from an antibody, a peptide, a vaccine, or a combination thereof.
75. The kit of claim 73, wherein said Hsp90 inhibitor comprises from luminespib, ganetespib, onalespib, 17-AAG, SNX-5422, XL-888, BIIB-021, zelavespib, 17- DMAG, BUB-028, DS 2248, retaspimycin, arimoclomol, CTXT-102, SGX-301, RTA 901, T-2143, TAS-116, PU-AD, or a combination thereof, or a combination thereof.
76. The kit of any one of claim 72-75, wherein said cancer comprises lung cancer, colorectal cancer, urinary tract cancer, uterine cancer, stomach cancer, ovarian cancer, breast cancer, colon cancer, pancreatic cancer, or a combination thereof.
Citation Information
Patent Citations
Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20110118298A1
RESISTANT MUTANT 90 kDA HEAT SHOCK PROTEIN
US20160311871A1
Use of ATR inhibitors in combination with PARP inhibitors
US20210177856A1
Biomarkers for cancer therapy using MDM2 antagonists
WO2022185260A1
